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Beware of using invalid 
transmission models to 
guide HIV health policy
Jeﬀ rey Eaton and colleagues 
(January, p e23)1 used modelling 
to inform international guide-
lines for antiretroviral therapy 
for HIV. Speciﬁ cally, they under-
took a comparative cost–effective-
ness  analysis based on predictions 
from 12 independent transmission 
models: seven were used for South 
Africa, four for Zambia, four for 
India, and one for Vietnam. They 
concluded that all 12 models 
show similar results—that earlier 
eligibility for antiretroviral therapy 
is cost eﬀ ective.1 They implied that 
their consensus ﬁ nding increases 
conﬁdence in the use of modelling 
results to guide HIV health policy.
The comparative consensus model-
ling approach used by Eaton and 
colleagues is now used frequently to 
justify the implementation of particular 
HIV interventions.1–3 However, this 
approach produces meaningful results 
only if the comparison is based on valid 
models. Most comparative consensus 
studies (including that by Eaton and 
colleagues) have not checked for 
model validity. 
We checked the validity of the 
seven South African models that 
Eaton and colleagues used by 
reproducing some of their numerical 
simulations (ﬁ gure). A valid model 
should accurately reﬂ ect the current 
state of the epidemic. Notably, 
we show that not all of the South 
African models agree on the present 
state of the epidemic; consequently, 
they cannot all be valid. Two 
models estimate that, at present, 
the epidemic (ie, incidence) is fairly 
stable, three that it is gradually 
decreasing, and two that it is rapidly 
decreasing (ﬁ gure). One can only 
have conﬁ dence in the results from 
a comparative analysis if it is based 
on valid models. Only then can a 
comparative consensus approach be 
useful to guide health policy. 
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Figure: Scenarios generated from seven diﬀ erent mathematical models used by Eaton and colleagues1 
For each model, the projected trend in incidence is based on the same assumption: that treatment conditions 
(ie, treatment eligibility criteria and coverage) remain the same as they are presently. Hence it can be seen that, 
under existing treatment conditions, two models estimate that the epidemic (ie, incidence) in South Africa is 
fairly stable (blue lines), three that it is gradually decreasing (green lines), and two that it is rapidly decreasing 
(red lines). These results were reproduced from data shown in ﬁ gure 2 of Eaton and colleagues’ article.1
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